15,071 results on '"Anti-Arrhythmia Agents therapeutic use"'
Search Results
2. Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation.
- Author
-
Kim YG, Lee HS, Kim H, and Choi JI
- Subjects
- Humans, Atrial Fibrillation drug therapy, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects, Bradycardia chemically induced
- Published
- 2024
- Full Text
- View/download PDF
3. Can the efficacy of a medical treatment be predicted based on the type of idiopathic premature ventricular contraction?
- Author
-
Atici A, Sahin I, Doğan Ö, Barman HA, Kup A, Celik M, Demirkiran A, Yilmaz Y, Ozcan FB, Cevik E, Orta H, Yılmaz M, Soysal AU, Yumuk MT, Yavuz ST, Öztürk F, Karaduman M, Yilmaz İ, and Caliskan M
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Treatment Outcome, Anti-Arrhythmia Agents therapeutic use, Calcium Channel Blockers therapeutic use, Adult, Reproducibility of Results, Ventricular Premature Complexes drug therapy, Ventricular Premature Complexes physiopathology, Electrocardiography, Adrenergic beta-Antagonists therapeutic use
- Abstract
Background: Premature ventricular contractions (PVCs) are common arrhythmias with diverse clinical implications. This retrospective study aimed to evaluate the efficacy of medical treatments using various clinical, imaging, and electrocardiographic parameters in patients with idiopathic PVCs., Methods: A total of 1051 patients with idiopathic PVCs were retrospectively analyzed. Patients were categorized into three groups based on treatment response: beta-blocker (BB) responders (479 patients), calcium-channel blocker (CCB) responders (335 patients), and class 1c antiarrhythmic (AA) responders (237 patients). Clinical, imaging, and electrocardiographic data were collected and analyzed to assess the factors influencing treatment response., Results: Age, left ventricular ejection fraction (LVEF), PVC QRS duration, CI variability, and multiple PVC morphologies were identified as significant factors affecting treatment response. Older age and lower LVEF were associated with better response to BB treatment, whereas CCB responders showed narrower QRS complexes. BB responders also exhibited higher CI variability, possibly linked to automaticity mechanisms. Moreover, the BB responder group had a higher frequency of multiple PVC morphologies., Conclusion: These findings emphasize the importance of tailored treatment approaches based on individual patient characteristics., Competing Interests: Declaration of competing interest All the authors declare no conflict of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Fine-tuning early rhythm control strategies for atrial fibrillation-Timing matters to stay in sync.
- Author
-
Vandenberk B and Chew DS
- Subjects
- Humans, Anti-Arrhythmia Agents therapeutic use, Time Factors, Atrial Fibrillation physiopathology, Atrial Fibrillation therapy, Heart Rate physiology
- Abstract
Competing Interests: Disclosures D.C. reports grant support from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. B.V. reports no relevant disclosures.
- Published
- 2024
- Full Text
- View/download PDF
5. Harnessing Cardiac Autonomic Control for Antiarrhythmic Therapy.
- Author
-
Ajijola OA and Aksu T
- Subjects
- Humans, Anti-Arrhythmia Agents therapeutic use, Heart physiology, Autonomic Nervous System physiopathology, Arrhythmias, Cardiac physiopathology
- Abstract
Competing Interests: Disclosure O.A. Ajijola reports support by NIH/NHLBI grants R01HL159001, R01HL162717, and HL P01HL164311, the Chan Zuckerberg Initiative, and the Leducq Foundation. T. Aksu reports no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
6. Characterization of remodeling processes in the atria of atrioventricular block dogs: Utility as an early-stage atrial fibrillation model.
- Author
-
Kambayashi R, Goto A, Takahara A, Saito H, Izumi-Nakaseko H, Takei Y, Akie Y, Hori M, and Sugiyama A
- Subjects
- Animals, Dogs, Male, Anti-Arrhythmia Agents pharmacology, Anti-Arrhythmia Agents therapeutic use, Echocardiography, Amiodarone pharmacology, Atrial Fibrillation physiopathology, Atrial Fibrillation etiology, Atrioventricular Block physiopathology, Heart Atria physiopathology, Heart Atria pathology, Disease Models, Animal, Atrial Remodeling physiology
- Abstract
To characterize utility of atrioventricular block (AVB) dogs as atrial fibrillation (AF) model, we studied remodeling processes occurring in their atria in acute (<2 weeks) and chronic (>4 weeks) phases. Fifty beagle dogs were used. Holter electrocardiogram demonstrated that paroxysmal AF occurred immediately after the production of AVB, of which duration tended to be prolonged in chronic phase. Electrophysiological analysis showed that inter-atrial conduction time and duration of burst pacing-induced AF increased in the chronic phase compared with those in the acute phase, but that atrial effective refractory period was hardly altered. Echocardiographic study revealed that diameters of left atrium, right pulmonary vein and inferior vena cava increased similarly in the acute and chronic phases. Histological evaluation indicated that hypertrophy and fibrosis in atrial tissue increased in the chronic phase. Electropharmacological characterization showed that i.v. pilsicainide effectively suppressed burst pacing-induced AF with increasing atrial conduction time and refractoriness of AVB dogs in chronic phase, but that i.v. amiodarone did not exert such electrophysiological effects. Taken together, AVB dogs in chronic phase appear to possess such pathophysiology as developed in the atria of early-stage AF patients, and therefore they can be used to evaluate drug candidates against early-stage AF., Competing Interests: Declaration of competing interest The authors declare no potential conflicts of interest except for H.S. and Y.A., who were employees of CMIC Pharma Science Co., Ltd., (Copyright © 2024 The Authors. Production and hosting by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Predictors and incidence of health status deterioration in patients with early atrial fibrillation.
- Author
-
Miyama H, Ikemura N, Kimura T, Katsumata Y, Yamashita S, Yamaoka K, Ibe S, Sekine O, Ueda I, Nakamura I, Negishi K, Kohsaka S, Takatsuki S, and Ieda M
- Subjects
- Humans, Male, Female, Incidence, Aged, Prospective Studies, Middle Aged, Registries, Anti-Arrhythmia Agents therapeutic use, Follow-Up Studies, Risk Factors, Prognosis, Catheter Ablation methods, Time Factors, Atrial Fibrillation epidemiology, Atrial Fibrillation therapy, Atrial Fibrillation complications, Atrial Fibrillation physiopathology, Health Status, Quality of Life
- Abstract
Background: Various treatment approaches for atrial fibrillation (AF) have demonstrated improved health status, yet the significance of these therapeutic interventions in individual patients remains unclear., Objective: This study aimed to evaluate health status changes in patients with early AF, focusing on those who experience clinically significant deterioration after treatment initiation., Methods: We analyzed data from a multicenter, prospective registry of newly diagnosed patients with AF. One-year changes in health status across different treatment strategies were assessed by the Atrial Fibrillation Effect on QualiTy-of-life Overall Summary (AFEQT-OS) score. Clinically relevant deterioration and improvement in health status were defined as ≥5-point decrease and increase in AFEQT-OS score, respectively; no change was -5 to 5 points., Results: Overall, 1960 patients with AF were evaluated. Mean AFEQT-OS scores at baseline and 1-year follow-up were 76.7 ± 17.7 and 85.4 ± 14.8, respectively. Although most patients (53.9%) experienced clinically important improvement, a considerable proportion had no change (28.7%) or deterioration (17.4%) in their health status. Proportions of patients with no change or deterioration varied by treatment strategy: 59.9%, 53.9%, and 32.0% in rate control, antiarrhythmic drug, and catheter ablation groups, respectively. The multivariable model identified older age, female sex, heart failure, coronary artery disease, and higher baseline AFEQT-OS score as independent predictors of worsening health status, regardless of treatment strategy., Conclusion: Many patients with early AF experience worsening or no change in health status irrespective of treatment strategy. Standardizing patients' health status assessment, especially for patients with comorbidities, may aid in patients' selection and their outcomes., Competing Interests: Disclosures Dr Ikemura received an unrestricted research grant from the Department of Cardiology, Keio University School of Medicine, Bristol-Myers Squibb, Japan. Dr Kohsaka received an unrestricted research grant from the Department of Cardiology at Keio University School of Medicine from Bayer Pharmaceutical and Daiichi Sankyo, grants from Bayer Yakuhin, Ltd and Daiichi Sankyo, and personal fees from Bristol-Myers Squibb. Dr Kimura received grants from Bayer Yakuhin Ltd. Dr Takatsuki received grants and personal fees from Bayer and personal fees from Daiichi Sankyo. The other authors declare no conflicts of interest., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
8. Practice patterns of rate control in atrial fibrillation and clinical outcomes from a nationwide cohort.
- Author
-
Frick W, Zhang Z, Rogers L, Rojulpote C, and Lin CJ
- Subjects
- Humans, Female, Male, Aged, United States epidemiology, Middle Aged, Digoxin therapeutic use, Heart Rate physiology, Heart Rate drug effects, Heart Failure epidemiology, Heart Failure drug therapy, Heart Failure physiopathology, Treatment Outcome, Hospitalization statistics & numerical data, Retrospective Studies, Databases, Factual, Aged, 80 and over, Stroke Volume physiology, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Practice Patterns, Physicians' statistics & numerical data, Anti-Arrhythmia Agents therapeutic use, Adrenergic beta-Antagonists therapeutic use, Calcium Channel Blockers therapeutic use
- Abstract
Atrial fibrillation (AF) is common, but there are limited data to guide selection of rate control medications (RCM). Reasons for selection are multivariable, and the impact on outcomes is unknown. We investigated prescribing patterns of RCM among patients with AF. Using a nationwide database, we identified 135,927 patients with AF. We stratified by baseline presence of heart failure with reduced ejection fraction (HFrEF) and examined prescription rates of RCM as a function of clinical variables. We also evaluated associations with clinical outcomes. Beta blockers (BB) were most commonly prescribed (44.6%), then calcium channel blockers (CCB) (14.0%) and digoxin (8.6%). Patients prescribed BB were more likely male (45.6% vs 43.4%, p < 0.0001), patients prescribed CCB were less likely male (12.0% vs 16.3%, p < 0.0001). There were higher rates of HF hospitalization (HFH) among females and those with Medicaid. Randomized trials are needed to define optimal choice of RCM., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. 3-N-Butylphthalide Confers Antiarrhythmic Features in Ischemia/Reperfusion Injury of Diabetic Heart by Targeting Mitochondria-Endoplasmic Reticulum Network and Inhibiting Oxidative Stress and Inflammation.
- Author
-
Han R and Duan B
- Subjects
- Animals, Male, Rats, Anti-Arrhythmia Agents pharmacology, Anti-Arrhythmia Agents therapeutic use, Mitochondria, Heart metabolism, Mitochondria, Heart drug effects, Inflammation metabolism, Inflammation drug therapy, Rats, Sprague-Dawley, Oxidative Stress drug effects, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury drug therapy, Myocardial Reperfusion Injury prevention & control, Benzofurans pharmacology, Benzofurans therapeutic use, Diabetes Mellitus, Experimental metabolism, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental complications, Arrhythmias, Cardiac etiology, Arrhythmias, Cardiac prevention & control, Arrhythmias, Cardiac metabolism, Arrhythmias, Cardiac drug therapy, Endoplasmic Reticulum Stress drug effects
- Abstract
While 3-N-butylphthalide (NBP) has demonstrated notable cardioprotective effects, its precise role in mitigating myocardial arrhythmia following ischemia/reperfusion (IR) injury in diabetes remains unclear. This study aimed to explore the potential mechanisms through which NBP mitigates reperfusion-induced myocardial arrhythmia in diabetic rats, with a particular focus on mitochondrial function and biogenesis, endoplasmic reticulum (ER) stress, and oxidative/inflammatory responses. Sixty Sprague-Dawley rats were divided into non-diabetic and diabetic groups, subjected to in-vivo myocardial IR injury, and treated with NBP (100 mg/kg, intraperitoneally) through different modalities: preconditioning, postconditioning, or a combination of both. Electrocardiography (ECG) was employed to assess the incidence and severity of arrhythmia. Fluorometric, Western blotting and ELISA analyses were utilized to measure the mitochondrial, ER stress, and cellular outcomes. Treatment of non-diabetic rats with NBP in preconditioned, postconditioned, and combined approaches significantly reduced cardiotroponin-I and the frequency and severity of arrhythmias induced by IR injury. However, only the combined preconditioning plus postconditioning approach of NBP had protective and antiarrhythmic effects in diabetic rats, in an additive manner. Moreover, the NBP combined approach improved mitochondrial function and upregulated the expression of PGC-1?, Sirt1, and glutathione while concurrently downregulating ER stress and oxidative and pro-inflammatory-related proteins in diabetic rats. In conclusion, the combined approach of NBP treatment was effective in mitigating myocardial arrhythmia in diabetic rats. This approach coordinates interactions within the mitochondria-endoplasmic reticulum network and inhibits oxidative and inflammatory mediators, offering a promising strategy for managing myocardial arrhythmia in diabetic patients. Key words: Myocardial Infarction, Mitochondria, Arrhythmia, Reperfusion, Diabetes, Ischemia.
- Published
- 2024
10. The Effects of Silymarin on Calcium Chloride-Induced Arrhythmia in Male Rat.
- Author
-
Toghroli F, Noorbakhsh MF, and Sajedianfard J
- Subjects
- Animals, Male, Rats, Rats, Sprague-Dawley, Anti-Arrhythmia Agents pharmacology, Anti-Arrhythmia Agents therapeutic use, Electrocardiography, Antioxidants pharmacology, Antioxidants therapeutic use, Silymarin pharmacology, Silymarin therapeutic use, Arrhythmias, Cardiac drug therapy, Arrhythmias, Cardiac chemically induced, Calcium Chloride pharmacology
- Abstract
Antioxidants play an important role in protecting cardiac arrhythmias. Silymarin, strong antioxidant, is effective in reducing the complications caused by arrhythmias. This study was conducted to determine the effect of silymarin on the prevention and treatment of calcium chloride-induced arrhythmia. In total, 48 male rats were randomly divided into six groups: the first control group for acute administration received intravenous injection of 0.2 mL of dimethylsulfoxide, a cosolvent, immediately after induction of arrhythmia; the second control group for chronic administration, daily gavage of dimethylsulfoxide for 2 weeks before induction of arrhythmia; acute silymarin group, 100 mg/kg intravenous, immediately after the occurrence of arrhythmia; chronic silymarin group, daily gavage of 50 mg/kg for 2 weeks before induction of arrhythmia; amiodarone standard treatment, 5 mg/kg intravenous, immediately after induction of arrhythmia; and quinidine standard treatment, 10 mg/kg intravenous, immediately after induction of arrhythmia. Calcium chloride (140 mg/kg, i.v.) was used to induce arrhythmia. Electrocardiogram was recorded and monitored by PowerLab™ system. The incidence rates of premature ventricular beat (PVB), ventricular tachycardia (VT), and ventricular fibrillation (VF) were calculated. The antiarrhythmic effect of silymarin was observed with a significant decrease in the incidence of premature ventricular beat (22.56 ± 1.04%, P < 0.001), ventricular tachycardia (34.150 ± 1.59%, P < 0.001), and ventricular fibrillation (24.31 ± 1.02%, P < 0.001) compared with the control group (100%). These effects were comparable to antiarrhythmic drugs such as quinidine (29.23% ± 1.24%, 52.23% ± 1.13%, 66.31% ± 1.81%) and amiodarone (22.91% ± .72%, 41.09% ± 1.66%, 61.59% ± 1.11%). Silymarin exerts a potent antioxidant effect, thereby mitigating the risk of VT, VF, and PVC., Competing Interests: The authors declare that there are no conflicts of interest., (Copyright © 2024 Fereshteh Toghroli et al.)
- Published
- 2024
- Full Text
- View/download PDF
11. Insights into the prospects of nanobiomaterials in the treatment of cardiac arrhythmia.
- Author
-
Lu D and Fan X
- Subjects
- Humans, Animals, Drug Delivery Systems, Nanotechnology methods, Tissue Engineering methods, Anti-Arrhythmia Agents therapeutic use, Arrhythmias, Cardiac therapy, Nanostructures therapeutic use, Nanostructures chemistry, Biocompatible Materials chemistry
- Abstract
Cardiac arrhythmia, a disorder of abnormal electrical activity of the heart that disturbs the rhythm of the heart, thereby affecting its normal function, is one of the leading causes of death from heart disease worldwide and causes millions of deaths each year. Currently, treatments for arrhythmia include drug therapy, radiofrequency ablation, cardiovascular implantable electronic devices (CIEDs), including pacemakers, defibrillators, and cardiac resynchronization therapy (CRT). However, these traditional treatments have several limitations, such as the side effects of medication, the risks of device implantation, and the complications of invasive surgery. Nanotechnology and nanomaterials provide safer, effective and crucial treatments to improve the quality of life of patients with cardiac arrhythmia. The large specific surface area, controlled physical and chemical properties, and good biocompatibility of nanobiomaterials make them promising for a wide range of applications, such as cardiovascular drug delivery, tissue engineering, and the diagnosis and therapeutic treatment of diseases. However, issues related to the genotoxicity, cytotoxicity and immunogenicity of nanomaterials remain and require careful consideration. In this review, we first provide a brief overview of cardiac electrophysiology, arrhythmia and current treatments for arrhythmia and discuss the potential applications of nanobiomaterials before focusing on the promising applications of nanobiomaterials in drug delivery and cardiac tissue repair. An in-depth study of the application of nanobiomaterials is expected to provide safer and more effective therapeutic options for patients with cardiac arrhythmia, thereby improving their quality of life., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. Evaluation of the management of a first crisis of atrial fibrillation in a group of Cameroon's urban setting subjects.
- Author
-
Tasong LAM, Nganou-Gnindjio CN, Yemele HK, Elong JT, Kuate LMM, Kuissu S, and Menanga AP
- Subjects
- Humans, Cameroon epidemiology, Male, Female, Retrospective Studies, Aged, Middle Aged, Treatment Outcome, Risk Factors, Aged, 80 and over, Time Factors, Anticoagulants therapeutic use, Anticoagulants adverse effects, Urban Health, Comorbidity, Heart Rate drug effects, Risk Assessment, Practice Patterns, Physicians' trends, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Atrial Fibrillation physiopathology, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects
- Abstract
Background: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. When atrial fibrillation is first diagnosed, it tends to be permanent and associated with significant morbidity and mortality. We aimed to study the management of a first episode of atrial fibrillation in a group of patients in Yaounde, Cameroon., Methods: We conducted a retrospective study with data collected from the Cardiology department of Yaounde Central Hospital and the internal medicine department of Yaounde General Hospital over five years (January 2017 to December 2021), for a duration of 4 months, from February 2022 to May 2022. All patients older than 15 years with a first episode of atrial fibrillation were included, and all patients with incomplete medical records were excluded. The association between different variables was assessed using a χ² test and logistic regression method with a significance threshold of p < 0.05., Results: Of the 141 patients recruited, the mean age was 68.5 ± 10.6 years. The sex ratio (M/F) was 0.7. The main associated factors and co-morbidities were hypertension in 70.2% (99) patients, heart failure in 36.9% (52) patients and a sedentary lifestyle in 33.3% (47) patients. The most common anticoagulant treatment was AntiVitamin K, used in 64.5% (91) of patients. Heart rate control was the most commonly used symptom control strategy in 85.1% (120) patients, mainly with beta-blockers in 52.5% (74). We found 1.4% (2) participants who were not treated with antithrombotics as recommended. Treatment of arrhythmia due to co-morbidities was not always recommended. The complication rate was 94.3% (133) patients. Control of the bleeding risk due to antithrombotic therapy and monitoring of anticoagulant therapy were not optimal. The heart rate control strategy had a higher success rate, and the sinus rhythm maintenance rate at one year was 61.7% (37) participants., Conclusion: The management of a first episode of atrial fibrillation at Yaoundé's Central and General Hospitals is not always performed according to current recommendations and is far from optimal. However, nearly two out of three patients maintained sinus rhythm for one year., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease.
- Author
-
Wang SR, Huang KC, Lin TT, Chuang SL, Yang YY, Wu CK, and Lin LY
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Dronedarone therapeutic use, Dronedarone adverse effects, Follow-Up Studies, Amiodarone therapeutic use, Amiodarone adverse effects, Amiodarone analogs & derivatives, Treatment Outcome, Retrospective Studies, Cohort Studies, Atrial Fibrillation drug therapy, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects, Coronary Artery Disease drug therapy, Coronary Artery Disease epidemiology
- Abstract
Background: While current guidelines recommend amiodarone and dronedarone for rhythm control in patients with atrial fibrillation (AF) and coronary artery disease (CAD), there was no comparative study of antiarrhythmic drugs (AADs) on the cardiovascular outcomes in general practice., Methods: This study included patients with AF and CAD who received their first prescription of amiodarone, class Ic AADs (flecainide, propafenone), dronedarone or sotalol between January 2016 and December 2020. The primary outcome was a composite of hospitalization for heart failure (HHF), stroke, acute myocardial infarction (AMI), and cardiovascular death. We used Cox proportional regression models, including with inverse probability of treatment weighting (IPTW), to estimate the relationship between AADs and cardiovascular outcomes., Results: Among the AF cohort consisting of 8752 patients, 1996 individuals had CAD, including 477 who took dronedarone and 1519 who took other AADs. After a median follow-up of 38 months, 46.3% of patients who took dronedarone and 54.4% of patients who took other AADs experienced cardiovascular events. Compared to dronedarone, the use of other AADs was associated with increased cardiovascular events after adjusting for covariates (hazard ratio [HR] 1.531, 95% confidence interval [CI] 1.112-2.141, p = 0.023) and IPTW (HR 1.491, 95% CI 1.174-1.992, p = 0.012). The secondary analysis showed that amiodarone and class Ic drugs were associated with an increased risk of HHF. The low number of subjects in the sotalol group limits data interpretation., Conclusion: For patients with AF and CAD, dronedarone was associated with better cardiovascular outcomes than other AADs. Amiodarone and class Ic AADs were associated with a higher risk of cardiovascular events, particularly HHF., Competing Interests: Declaration of competing interest The corresponding author has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conflict of interests is none., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients.
- Author
-
Crotti L, Neves R, Dagradi F, Musu G, Giannetti F, Bos JM, Barbieri M, Cerea P, Giovenzana FLF, Torchio M, Mura M, Gnecchi M, Conte G, Auricchio A, Sala L, Odening KE, Ackerman MJ, and Schwartz PJ
- Subjects
- Animals, Humans, Rabbits, Male, Female, Adult, Action Potentials drug effects, Anti-Arrhythmia Agents pharmacology, Anti-Arrhythmia Agents therapeutic use, Adolescent, Middle Aged, Young Adult, ERG1 Potassium Channel genetics, ERG1 Potassium Channel antagonists & inhibitors, ERG1 Potassium Channel metabolism, Heart Rate drug effects, Disease Models, Animal, Child, Treatment Outcome, Mexiletine pharmacology, Mexiletine therapeutic use, Myocytes, Cardiac drug effects, Long QT Syndrome drug therapy, Long QT Syndrome physiopathology, Long QT Syndrome genetics, Induced Pluripotent Stem Cells drug effects, Animals, Genetically Modified
- Abstract
Background: Despite major advances in the clinical management of long QT syndrome, some patients are not fully protected by beta-blocker therapy. Mexiletine is a well-known sodium channel blocker, with proven efficacy in patients with sodium channel-mediated long QT syndrome type 3. Our aim was to evaluate the efficacy of mexiletine in long QT syndrome type 2 (LQT2) using cardiomyocytes derived from patient-specific human induced pluripotent stem cells, a transgenic LQT2 rabbit model, and patients with LQT2., Methods: Heart rate-corrected field potential duration, a surrogate for QTc, was measured in human induced pluripotent stem cells from 2 patients with LQT2 (KCNH2-p.A561V, KCNH2-p.R366X) before and after mexiletine using a multiwell multi-electrode array system. Action potential duration at 90% repolarization (APD
90 ) was evaluated in cardiomyocytes isolated from transgenic LQT2 rabbits (KCNH2-p.G628S) at baseline and after mexiletine application. Mexiletine was given to 96 patients with LQT2. Patients were defined as responders in the presence of a QTc shortening ≥40 ms. Antiarrhythmic efficacy of mexiletine was evaluated by a Poisson regression model., Results: After acute treatment with mexiletine, human induced pluripotent stem cells from both patients with LQT2 showed a significant shortening of heart rate-corrected field potential duration compared with dimethyl sulfoxide control. In cardiomyocytes isolated from LQT2 rabbits, acute mexiletine significantly shortened APD90 by 113 ms, indicating a strong mexiletine-mediated shortening across different LQT2 model systems. Mexiletine was given to 96 patients with LQT2 either chronically (n=60) or after the acute oral drug test (n=36): 65% of the patients taking mexiletine only chronically and 75% of the patients who performed the acute oral test were responders. There was a significant correlation between basal QTc and ∆QTc during the test ( r = -0.8; P <0.001). The oral drug test correctly predicted long-term effect in 93% of the patients. Mexiletine reduced the mean yearly event rate from 0.10 (95% CI, 0.07-0.14) to 0.04 (95% CI, 0.02-0.08), with an incidence rate ratio of 0.40 (95% CI, 0.16-0.84), reflecting a 60% reduction in the event rate ( P =0.01)., Conclusions: Mexiletine significantly shortens cardiac repolarization in LQT2 human induced pluripotent stem cells, in the LQT2 rabbit model, and in the majority of patients with LQT2. Furthermore, mexiletine showed antiarrhythmic efficacy. Mexiletine should therefore be considered a valid therapeutic option to be added to conventional therapies in higher-risk patients with LQT2., Competing Interests: None.- Published
- 2024
- Full Text
- View/download PDF
15. Omega-3 Fatty Acids and Arrhythmias.
- Author
-
Marcus MD and Link MS
- Subjects
- Humans, Animals, Atrial Fibrillation prevention & control, Atrial Fibrillation drug therapy, Death, Sudden, Cardiac prevention & control, Death, Sudden, Cardiac etiology, Anti-Arrhythmia Agents therapeutic use, Dietary Supplements, Eicosapentaenoic Acid analogs & derivatives, Eicosapentaenoic Acid therapeutic use, Randomized Controlled Trials as Topic, Docosahexaenoic Acids therapeutic use, Fatty Acids, Omega-3 therapeutic use, Arrhythmias, Cardiac prevention & control
- Abstract
The pro- and antiarrhythmic effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been extensively studied in preclinical and human trials. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit. Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden cardiac death, but these findings have not been widely replicated, and the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to reduce arrhythmic death in combination, or as monotherapy, remains uncertain. The accumulated clinical evidence does not support supplementation of n-3 PUFA for postoperative AF or secondary prevention of AF. Several large, contemporary, randomized controlled trials of high-dose n-3 PUFA for primary or secondary cardiovascular prevention have demonstrated a small, significant, dose-dependent increased risk of incident AF compared with mineral oil or corn oil comparator. These findings were reproduced with both icosapent ethyl monotherapy and a mixed EPA+DHA formulation. The proarrhythmic mechanism of increased AF in contemporary cohorts exposed to high-dose n-3 PUFA is unknown. EPA and DHA and their metabolites have pleiotropic cardiometabolic and pro- and antiarrhythmic effects, including modification of the lipid raft microenvironment; alteration of cell membrane structure and fluidity; modulation of sodium, potassium, and calcium currents; and regulation of gene transcription, cell proliferation, and inflammation. Further characterization of the complex association between EPA, EPA+DHA, and DHA and AF is needed. Which formulations, dose ranges, and patient subgroups are at highest risk, remain unclear., Competing Interests: None.
- Published
- 2024
- Full Text
- View/download PDF
16. General anaesthesia compared to conscious sedation for first-time atrial fibrillation catheter ablation-a Danish nationwide cohort study.
- Author
-
Riis-Vestergaard LD, Tønnesen J, Ruwald MH, Zörner CR, Middelfart C, Hein R, Johannessen A, Hansen J, Worck RH, Gislason G, and Hansen ML
- Subjects
- Humans, Male, Female, Denmark epidemiology, Middle Aged, Aged, Treatment Outcome, Risk Factors, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation surgery, Atrial Fibrillation epidemiology, Anesthesia, General statistics & numerical data, Catheter Ablation statistics & numerical data, Conscious Sedation statistics & numerical data, Recurrence, Registries
- Abstract
Aims: Catheter ablation (CA) is a well-established treatment option for atrial fibrillation (AF), where sedation and analgesia are pivotal for patient comfort and lesion formation. The impact of anaesthesia type on AF recurrence rates remains uncertain. This study aimed to examine AF recurrence rates depending on conscious sedation (CS) vs. general anaesthesia (GA) during CA., Methods and Results: Utilizing nationwide data from the Danish healthcare registries, we conducted this cohort study involving adults (≥18 years) undergoing first-time CA for AF between 2010 and 2018. Patients were categorized by anaesthesia type (CS or GA), with the primary endpoint being AF recurrence, defined by a composite endpoint of either antiarrhythmic drug (AAD) prescriptions, AF-related hospital admissions, electrical cardioversions, or AF re-ablation. The impact of anaesthesia type was evaluated using multivariable Cox proportional hazards analysis. The study cohort comprised 7957 (6421 CS and 1536 GA) patients. Persistent AF, hypertension, and heart failure, as well as use of AAD, were more prevalent in the GA group. Cumulative incidences of recurrent AF were higher in the CS group at 1 (46% vs. 37%) and at 5 (68% vs. 63%) years. Multivariate analysis revealed CS as significantly associated with increased risk of AF recurrence at 5-year follow-up [hazard ratio 1.26 (95% confidence interval 1.15-1.38)], consistent across paroxysmal and persistent AF subtypes., Conclusion: This nationwide cohort study suggests a higher risk of AF recurrence with CS during CA compared to GA. These results advocate for considering GA as the preferred anaesthesia type for improved CA outcomes., Competing Interests: Conflict of interest: L.D.R.-V., J.T., C.R.Z., C.M., R.H., A.J., R.H.W., G.G.: none. M.H.R.: Speaker honoraria from Boston Scientific and CardioFocus. J.H.: Speaker fees and consultant honoraria from Boston Scientific and Biosense Webster. M.L.H.: Received research grants from Biosense Webster and Medtronic., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
17. Long QT syndrome: importance of reassessing arrhythmic risk after treatment initiation.
- Author
-
Dusi V, Dagradi F, Spazzolini C, Crotti L, Cerea P, Giovenzana FLF, Musu G, Pedrazzini M, Torchio M, and Schwartz PJ
- Subjects
- Humans, Female, Male, Adult, Risk Assessment, Young Adult, Adolescent, Child, Middle Aged, Death, Sudden, Cardiac prevention & control, Death, Sudden, Cardiac etiology, Anti-Arrhythmia Agents therapeutic use, Child, Preschool, Electrocardiography, Risk Factors, Long QT Syndrome therapy, Adrenergic beta-Antagonists therapeutic use, Defibrillators, Implantable
- Abstract
Background and Aims: Risk scores are proposed for genetic arrhythmias. Having proposed in 2010 one such score (M-FACT) for the long QT syndrome (LQTS), this study aims to test whether adherence to its suggestions would be appropriate., Methods: LQT1/2/3 and genotype-negative patients without aborted cardiac arrest (ACA) before diagnosis or cardiac events (CEs) below age 1 were included in the study, focusing on an M-FACT score ≥2 (intermediate/high risk), either at presentation (static) or during follow-up (dynamic), previously associated with 40% risk of implantable cardioverter defibrillator (ICD) shocks within 4 years., Results: Overall, 946 patients (26 ± 19 years at diagnosis, 51% female) were included. Beta-blocker (βB) therapy in 94% of them reduced the rate of those with a QTc ≥500 ms from 18% to 12% (P < .001). During 7 ± 6 years of follow-up, none died; 4% had CEs, including 0.4% with ACA. A static M-FACT ≥2 was present in 110 patients, of whom 106 received βBs. In 49/106 patients with persistent dynamic M-FACT ≥2, further therapeutic optimization (left cardiac sympathetic denervation in 55%, mexiletine in 31%, and ICD at 27%) resulted in just 7 (14%) patients with CEs (no ACA), with no CEs in the remaining 57. Additionally, 32 patients developed a dynamic M-FACT ≥2 but, after therapeutic optimization, only 3 (9%) had CEs. According to an M-FACT score ≥2, a total of 142 patients should have received an ICD, but only 22/142 (15%) were implanted, with shocks reported in 3., Conclusions: Beta-blockers often shorten QTc, thus changing risk scores and ICD indications for primary prevention. Yearly risk reassessment with therapy optimization leads to fewer ICD implants (3%) without increasing life-threatening events., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
18. Reply: Verapamil-Sensitive Idiopathic Left Ventricular Tachycardia Alongside Atrial Flutter.
- Author
-
Itoh T, Nishizaki K, Kimura M, and Tomita H
- Subjects
- Humans, Anti-Arrhythmia Agents therapeutic use, Electrocardiography, Atrial Flutter drug therapy, Atrial Flutter physiopathology, Tachycardia, Ventricular drug therapy, Tachycardia, Ventricular physiopathology, Verapamil therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
19. Verapamil-Sensitive Idiopathic Left Ventricular Tachycardia Alongside Atrial Flutter.
- Author
-
Belhassen B, Scheinman M, and Nogami A
- Subjects
- Humans, Case Reports as Topic, Catheter Ablation, Anti-Arrhythmia Agents therapeutic use, Atrial Flutter complications, Atrial Flutter drug therapy, Atrial Flutter physiopathology, Electrocardiography, Tachycardia, Ventricular complications, Tachycardia, Ventricular drug therapy, Tachycardia, Ventricular physiopathology, Verapamil therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
20. Antiarrhythmic preferences and outcomes post DC cardioversion for atrial fibrillation, an Australian rural perspective.
- Author
-
Thomas M, Elhindi J, Kamaladasa K, and Sirisena T
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, New South Wales, Middle Aged, Rural Population, Aged, 80 and over, Treatment Outcome, Atrial Fibrillation drug therapy, Atrial Fibrillation therapy, Anti-Arrhythmia Agents therapeutic use, Electric Countershock
- Abstract
Introduction: Direct current cardioversion (DCCV) remains one of the recommended management strategies for symptomatic atrial fibrillation (AF). Antiarrhythmic drugs (AAD) are prescribed post procedure to maintain sinus rhythm (SR). Limited literature exists on the AAD prescribing practices and their efficacy, post-DCCV in rural Australia., Objective: The primary aim was to determine the preferred AAD post-DCCV and the factors affecting AAD prescribing practices. The secondary aim was to assess the efficacy of the AAD in maintaining SR., Design: A retrospective observational audit of patients with non-valvular AF who underwent successful elective DCCV for symptomatic AF, during 2015-2020 at a regional hospital in New South Wales (NSW) (Dubbo Base Hospital). Patients were followed up for a duration of 12 months post-DCCV., Results: 233 patients underwent successful DCCV during the study duration. Amiodarone was the preferred AAD of choice post-DCCV followed by sotalol and flecainide, respectively (36.5% vs. 27.8% vs. 1.3%). 35.2% patients were not prescribed AAD. Amiodarone and sotalol had similar but modest efficacies and neither were superior to no AAD, in maintaining SR 12 months post-DCCV (AF recurrence rate 61.5% vs. 68.2% vs. 71.6% respectively, p = 0.37). Antecedent cerebrovascular accident (CVA), pulmonary disease, smoking, prior treatment with digoxin, diuretics and left ventricular (LV) dysfunction were factors that influenced AAD prescribing practices., Conclusion: The study demonstrates equal efficacies of amiodarone, sotalol and no AAD in maintaining SR 12 months post-DCCV. Prescribing practices post-DCCV at Dubbo Base Hospital differ from observed national trends and guidelines. AAD prescription requires a multifaceted approach with a key consideration to prioritise safety over efficacy, being mindful of challenges in delivering optimal healthcare in a rural setting., (© 2024 The Authors. Australian Journal of Rural Health published by John Wiley & Sons Australia, Ltd on behalf of National Rural Health Alliance Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
21. Spontaneous pre-excited supraventricular tachycardias in a Labrador Retriever.
- Author
-
Melis C, Beijerink N, and Santilli R
- Subjects
- Dogs, Animals, Male, Sotalol therapeutic use, Fatal Outcome, Lidocaine therapeutic use, Dog Diseases drug therapy, Tachycardia, Supraventricular veterinary, Tachycardia, Supraventricular drug therapy, Electrocardiography veterinary, Anti-Arrhythmia Agents therapeutic use
- Abstract
A four-year-old Labrador Retriever was presented for intermittent tachycardia. The electrocardiogram showed sinus rhythm conducted with ventricular pre-excitation and short runs of orthodromic atrioventricular reciprocating tachycardia. Four months later, the rhythm degenerated into a symptomatic sustained tachycardia, suspected to be pre-excited atrial fibrillation, a potentially life-threatening rhythm in the presence of an accessory pathway with a short refractory period. Two days after initiating oral diltiazem, the dog deteriorated and represented with sustained orthodromic atrioventricular reciprocating tachycardia, which was terminated by a precordial chest thump. It proceeded to sinus rhythm with ventricular pre-excitation followed by an episode of pre-excited focal atrial tachycardia. A bolus of lidocaine IV successfully restored sinus rhythm and sotalol treatment was started. The dog clinically recovered but died spontaneously 24 h later. This is the first case report that describes spontaneous pre-excited focal atrial tachycardia., Competing Interests: Conflict of Interest Statement The authors do not have any conflict of interest to disclose., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
22. Outcome of tailored therapy in rheumatic heart disease with persistent atrial fibrillation (RHD-AF).
- Author
-
Saggu DK, Subramaniam M, Korabathina R, Raju BS, Atreya AR, Reddy P, Kumar DN, Menon R, Yalagudri S, Kapadiya A, Chennapragada S, and Narasimhan C
- Subjects
- Humans, Female, Male, Middle Aged, Electric Countershock, Catheter Ablation methods, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation therapy, Atrial Fibrillation physiopathology, Rheumatic Heart Disease therapy, Rheumatic Heart Disease complications
- Abstract
Introduction: Rheumatic heart disease with persistent atrial fibrillation (RHD-AF) is associated with increased morbidity. However, there is no standardized approach for the maintenance of sinus rhythm (SR) in them. We aimed to determine the utility of a stepwise approach to achieve SR in RHD-AF., Methods: Consecutive patients with RHD-AF from July 2021 to August 2023 formed the study cohort. The stepwise approach included pharmacological rhythm control and/or electrical cardioversion (Central illustration). In patients with recurrence, additional options included AF ablation or pace and ablate strategy with conduction system pacing or biventricular pacing. Clinical improvement, NT-proBNP, 6-Minute Walk Test (6MWT), heart failure (HF) hospitalizations, and thromboembolic complications were documented during follow-up., Results: Eighty-three patients with RHD-AF (mean age 56.13 ± 9.51 years, women 72.28%) were included. Utilizing this approach, 43 (51.81%) achieved and maintained SR during the study period of 11.04 ± 7.14 months. These patients had improved functional class, lower NT-proBNP, better distance covered for 6MWT, and reduced HF hospitalizations. The duration of AF was shorter in patients who achieved SR, compared to those who remained in AF (3.15 ± 1.29 vs 6.93 ± 5.23, p = 0.041). Thirty-five percent (29) maintained SR after a single cardioversion over the study period. Only one underwent AF ablation. Of the 24 who underwent pace and ablate strategy, atrial lead was implanted in 22 (hybrid approach), and 50% of these achieved and maintained SR. Among these 24, none had HF hospitalizations, but patients who maintained SR had further improvement in clinical and functional parameters., Conclusions: RHD-AF patients who could achieve SR with a stepwise approach, had better clinical outcomes and lower HF hospitalizations., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
23. Failure of intravenous nifekalant cardioversion as an independent predictor for persistent atrial fibrillation recurrence after catheter ablation.
- Author
-
Ma Y, Guo L, Pang H, Yan Q, Li J, Hu M, and Yi F
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Treatment Failure, Electric Countershock, Risk Factors, Prognosis, Treatment Outcome, Aged, Atrial Fibrillation surgery, Atrial Fibrillation drug therapy, Recurrence, Catheter Ablation methods, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents administration & dosage, Pyrimidinones therapeutic use
- Abstract
Aims: Nifekalant is a class III antiarrhythmic drug that exerts antiarrhythmic effects by inhibiting rapid rectifying potassium channels and extending the effective refractory period of cardiomyocytes. It has a high success rate in converting atrial fibrillation (AF) to sinus rhythm. Whether the failure of intravenous nifekalant cardioversion is an independent predictor for persistent AF recurrence after catheter ablation has not been reported., Methods: A total of 92 patients with drug-refractory persistent AF were retrospectively enrolled. After all ablations, intravenous nifekalant was administrated. Patients were assigned to the success group (group 1) and failure group (group 2) based on nifekalant cardioversion results and followed for 12 months to note any episode of atrial arrhythmia recurrence., Results: Each group included 46 patients. After 12 months of follow-up, nine (19.6%) patients from group 1 and 23 (50.0%) patients from group 2 had a recurrence of atrial tachyarrhythmia (P = 0.002). AF duration and type 2 diabetes were strongly associated with failure of intravenous nifekalant cardioversion. Univariable Cox proportional hazard regression showed that failure of intravenous nifekalant cardioversion, AF duration, and type 2 diabetes were potential risk factors. Multivariable Cox proportional hazard regression showed that failure of nifekalant cardioversion was statistically associated with AF recurrence (adjusted RR = 2.257, 95% CI: 1.006-5.066, P = 0.048). Failure of intravenous nifekalant cardioversion could bring a positive effect on the prognostic differentiation when added into the multivariable model (0.767 ± 0.042 vs. 0.774 ± 0.045, P = 0.025)., Conclusion: Failure of nifekalant cardioversion is an independent predictor for persistent AF recurrence after catheter ablation., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
24. Outcomes in Infants with Supraventricular Tachycardia: Risk Factors for Readmission, Recurrence and Ablation.
- Author
-
Vari D, Kurek N, Zang H, Anderson JB, Spar DS, and Czosek RJ
- Subjects
- Humans, Retrospective Studies, Male, Female, Risk Factors, Infant, Anti-Arrhythmia Agents therapeutic use, Infant, Newborn, Treatment Outcome, Adrenergic beta-Antagonists therapeutic use, Tachycardia, Supraventricular therapy, Patient Readmission statistics & numerical data, Catheter Ablation, Recurrence
- Abstract
Supraventricular tachycardia (SVT) is the most common arrhythmia in infants. Once diagnosed, infants are admitted for antiarrhythmic therapy and discharged after observation. There are limited data on risk factors for readmission and readmission rates, while on medication. The objective of this study was to investigate risk factors for readmission and outcomes in infants diagnosed with SVT. This is a single-center retrospective study over a 10-year period of infants under 6 months of age with documented SVT. Infants with congenital heart disease requiring surgical or catheter intervention, gestational age less than 32 weeks or diagnosis of atrial flutter or fibrillation were excluded. The primary outcome was readmission within 31 days of hospital discharge. Long term need for ablation and eventual discontinuation of medications were assessed. Ninety patients were included. Beta blockers were the initial therapy in 66 and 28 required a medication change. Nineteen were readmitted within 31 days of discharge. The only clinical factor associated with early readmission was presence of ventricular pre-excitation (6/19 vs. 8/71, p = 0.03). Patients who were readmitted within 31 days had a longer length of treatment (12 [11.5, 22.0] vs. 10 [7.5, 12.0] months, p = 0.007) and were more likely to undergo ablation (4/19 vs. 2/71, p = 0.017). In this cohort of infants with SVT, readmission was common and ventricular pre-excitation was identified as a risk factor for readmission. Infants who were readmitted within 31 days of discharge had longer length of antiarrhythmic therapy and were more likely to undergo catheter ablation., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
25. Combination therapy of beta-blockers and digoxin is associated with increased risk of major adverse cardiovascular events and all-cause mortality in patients with atrial fibrillation: a report from the GLORIA-AF registry.
- Author
-
Lam SHM, Romiti GF, Olshansky B, Chao TF, Huisman MV, and Lip GYH
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Prospective Studies, Cardiovascular Diseases mortality, Cardiovascular Diseases drug therapy, Proportional Hazards Models, Propensity Score, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects, Digoxin therapeutic use, Adrenergic beta-Antagonists therapeutic use, Adrenergic beta-Antagonists adverse effects, Atrial Fibrillation drug therapy, Atrial Fibrillation complications, Atrial Fibrillation mortality, Registries statistics & numerical data, Drug Therapy, Combination
- Abstract
The effect of digoxin and beta-blockers on cardiovascular outcomes and mortality remains unclear. The study aimed to determine differences in cardiovascular (CV) outcomes and death rates among patients with atrial fibrillation (AF) who were prescribed with beta-blockers, digoxin or combination therapy. Data from phase II/III of the prospective Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) were analysed. The risk of major cardiovascular events (MACE) and death among patients with different prescriptions using COX proportional hazard regression was considered. Propensity score (PS) matching and weighting were further used to adjust for potential confounders of prescription use. A total of 14,201 patients [median age: 71.0 (IQR 64.0-77.0) years; 46.2% female] were recruited. After a median follow-up of 3.0 (IQR 2.4-3.1) years, 864 MACE, and 988 all-cause deaths were recorded. The incidence rate (IR) of MACE was 22.4 (95%CI 21.0-24.0) per 1000 person-years, while the IR of all-cause death was 25.4 (95%CI 23.8-27.0) per 1000 person-years. After multivariate adjustment with Cox regression, the risk of MACE (HR 1.35, 95% CI 1.09-1.68) and the risk of all-cause death (HR 1.28, 95%CI 1.04-1.57) were significantly higher in the combination therapy group, compared to the beta-blockers alone group. The risks of MACE and all-cause death remained significant in both PS matched and PS weighted cohort Among AF patients, combination therapy of beta-blockers and digoxin was associated with higher risks of MACE and all-cause death compared to beta-blockers alone., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
26. [Antiarrhythmic drugs in the present day].
- Author
-
Allgaier R and Duncker D
- Subjects
- Humans, Atrial Fibrillation drug therapy, Heart Failure drug therapy, Tachycardia, Ventricular drug therapy, Drug Interactions, Tachycardia, Supraventricular drug therapy, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects, Arrhythmias, Cardiac drug therapy, Arrhythmias, Cardiac chemically induced
- Abstract
Cardiac arrhythmias cause a significant proportion of hospitalizations and physician contacts worldwide. By using antiarrhythmic drugs, cardiac arrhythmias can be effectively treated and the frequency of recurrences reduced. Atrial fibrillation and heart failure represent diseases in which antiarrhythmic drugs are more often used on a long-term basis. The aim of this article is to provide an overview of the most common antiarrhythmic drugs and their uses as well as to provide recommendations for adequate handling and use, especially in the outpatient setting. In addition to long-term use, some antiarrhythmic drugs are also administered for the acute management of supraventricular or ventricular tachycardia. Relevant contraindications, side effects and interactions must be considered, meaning that patients should be followed up when using these potent drugs. This article shows in detail what to consider when using antiarrhythmic drugs in order to ensure not only effective but also safe treatment., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
27. Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial.
- Author
-
Gelbenegger G, Jilma B, Horvath LC, Schoergenhofer C, Siller-Matula JM, Sulzgruber P, Grassmann D, Hamp T, Grafeneder J, Schnaubelt S, Holzer M, and Krammel M
- Subjects
- Humans, Male, Double-Blind Method, Female, Pilot Projects, Middle Aged, Aged, Adrenergic beta-Antagonists administration & dosage, Adrenergic beta-Antagonists therapeutic use, Treatment Outcome, Amiodarone administration & dosage, Amiodarone analogs & derivatives, Amiodarone therapeutic use, Amiodarone adverse effects, Anti-Arrhythmia Agents administration & dosage, Anti-Arrhythmia Agents therapeutic use, Epinephrine administration & dosage, Ventricular Fibrillation drug therapy, Ventricular Fibrillation complications, Ventricular Fibrillation etiology, Out-of-Hospital Cardiac Arrest drug therapy, Out-of-Hospital Cardiac Arrest complications, Urea analogs & derivatives, Urea administration & dosage, Urea therapeutic use, Morpholines administration & dosage, Morpholines therapeutic use, Morpholines adverse effects
- Abstract
Background: Out-of-hospital cardiac arrest (OHCA) complicated by refractory ventricular fibrillation (VF) is associated with poor outcome. Beta-1-receptor selective blockade might overcome refractory VF and improve survival. This trial investigates the efficacy and safety of prehospital landiolol in OHCA and refractory VF., Methods: In this randomized, double-blind, placebo-controlled pilot trial, patients with OHCA and recurrent or refractory VF (at least 3 defibrillation attempts and last rhythm shockable), pretreated with epinephrine and amiodarone, were allocated to receive add-on treatment with landiolol or placebo. Landiolol was given as a 20 mg bolus infusion. The primary efficacy outcome was time from trial drug infusion to sustained return of spontaneous circulation (ROSC). Safety outcomes included the onset of bradycardia and asystole., Results: A total of 36 patients were enrolled, 19 were allocated to the landiolol group and 17 to the placebo group. Time from trial drug infusion to sustained ROSC was similar between treatment groups (39 min [landiolol] versus 41 min [placebo]). Sustained ROSC was numerically lower in the landiolol group compared with the placebo group (7 patients [36.8%] versus 11 patients [64.7%], respectively). Asystole within 15 min of trial drug infusion occurred significantly more often in the landiolol group than in the placebo group (7 patients [36.8%] and 0 patients [0.0%], respectively)., Conclusion: In patients with OHCA and refractory VF who are pretreated with epinephrine and amiodarone, add-on bolus infusion of landiolol 20 mg did not lead to a shorter time to sustained ROSC compared with placebo. Landiolol might be associated with bradycardia and asystole., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial.
- Author
-
Sapp JL, Tang ASL, Parkash R, Stevenson WG, Healey JS, and Wells G
- Subjects
- Humans, Male, Female, Defibrillators, Implantable, Middle Aged, Amiodarone therapeutic use, Treatment Outcome, Sotalol therapeutic use, Combined Modality Therapy, Tachycardia, Ventricular therapy, Anti-Arrhythmia Agents therapeutic use, Catheter Ablation methods, Cardiomyopathies complications, Cardiomyopathies therapy, Myocardial Ischemia complications
- Abstract
Background: Recurrent ventricular tachycardia (VT) in patients with prior myocardial infarction is associated with adverse quality of life and clinical outcomes, despite the presence of implanted defibrillators (ICDs). Suppression of recurrent VT can be accomplished with antiarrhythmic drug therapy or catheter ablation. The Ventricular Tachycardia Antiarrhythmics or Ablation In Structural Heart Disease 2 (VANISH2) trial is designed to determine whether ablation is superior to antiarrhythmic drug therapy as first line therapy for patients with ischemic cardiomyopathy and VT., Methods: The VANISH2 trial enrolls patients with prior myocardial infarction and VT (with one of: ≥1 ICD shock; ≥3 episodes treated with antitachycardia pacing (ATP) and symptoms; ≥5 episodes treated with ATP regardless of symptoms; ≥3 episodes within 24 hours; or sustained VT treated with electrical cardioversion or pharmacologic conversion). Enrolled patients are classified as either sotalol-eligible, or amiodarone-eligible, and then are randomized to either catheter ablation or to that antiarrhythmic drug therapy, with randomization stratified by drug-eligibility group. Drug therapy, catheter ablation procedures and ICD programming are standardized. All patients will be followed until two years after randomization. The primary endpoint is a composite of mortality at any time, appropriate ICD shock after 14 days, VT storm after 14 days, and treated sustained VT below detection of the ICD after 14 days. The outcomes will be analyzed according to the intention-to-treat principle using survival analysis techniques RESULTS: The results of the VANISH2 trial are intended to provide data to support clinical decisions on how to suppress VT for patients with prior myocardial infarction., Clinicaltrials: gov registration NCT02830360., Competing Interests: Conflict of Interest JLS: Research grants Johnson and Johnson; Abbott. Honoraria/Consulting Varian, Medtronic, Johnson and Johnson, Abbott. ASL: nothing to disclose. RP: Research grants Medtronic and Abbott. WGS: Research funding Adagio Medical; Honoraria Boston Scientific, Johnson, and Johnson, Medtronic, Abbott, Biotronik. JSH: Research grants Boston Scientific, BMS/Pfizer, Medtronic, Honoraria/Consulting: Boston Scientific, BMS/Pfizer, Servier, Novartis, Bayer. GW: nothing to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation.
- Author
-
Satti DI, Karius A, Chan JSK, Isakadze N, Yadav R, Garg K, Aronis KN, Marine JE, Berger R, Calkins H, and Spragg D
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Propensity Score, Treatment Outcome, Anti-Arrhythmia Agents therapeutic use, Glucagon-Like Peptide-1 Receptor Agonists, Atrial Fibrillation drug therapy, Atrial Fibrillation surgery, Catheter Ablation, Recurrence, Glucagon-Like Peptide-1 Receptor agonists
- Abstract
Background: Relationship between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use prior to atrial fibrillation (AF) ablation and subsequent AF recurrence is not well-understood., Objectives: This study investigated the effects of GLP-1 RA use within 1 year before ablation and its association with AF recurrence and associated outcomes., Methods: The TriNetX research database was used to identify patients aged ≥18 years undergoing AF ablation (2014-2023). Patients were categorized into 2 groups, and propensity score matching (1:1) between preablation GLP-1 RA users and nonusers was performed based on demographics, comorbidities, body mass index, laboratory tests, AF subtype, and medications. Primary outcome was composite of cardioversion, new antiarrhythmic drug therapy, or repeat AF ablation after a 3-month blanking period following the index ablation. Additional outcomes included ischemic stroke, all-cause hospitalization, and mortality during 12-month follow-up period., Results: After 1:1 propensity score matching, the study cohort comprised 1,625 GLP-1 RA users and 1,625 matched GLP-1 RA nonusers. Preablation GLP-1 RA therapy was not associated with a lower risk of cardioversion, new AAD therapy, and repeat AF ablation after the index procedure (HR: 1.04 [95% CI: 0.92-1.19]; log-rank P = 0.51). Furthermore, the risk of ischemic stroke, all-cause hospitalization, and mortality during the 12-month follow-up period did not differ between the 2 groups., Conclusions: These findings suggest that preprocedural use of GLP-1 RAs is not associated with a reduced risk of AF recurrence or associated adverse outcomes following ablation, and underscore the need for future research to determine whether these agents improve outcome in AF patients., Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. [Atrial fibrillation and heart failure].
- Author
-
Bergau L
- Subjects
- Humans, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation physiopathology, Atrial Fibrillation therapy, Heart Failure physiopathology, Catheter Ablation methods
- Abstract
Atrial fibrillation and heart failure are among the most common cardiovascular diseases and have a significant impact on the mortality and morbidity of affected patients. From a pathophysiological perspective, the two diseases are closely related and often perpetuate each other. Therefore, effective management of atrial fibrillation is now a central component of modern heart failure treatment. Based on current data, sinus rhythm should primarily be permanently maintained in patients with systolic heart failure. Catheter ablation has recently proven to be advantageous over purely pharmacological therapy and is therefore the treatment of choice for many patients with heart failure and atrial fibrillation. In patients with diastolic heart failure (heart failure with preserved ejection fraction [HFpEF]), the effect of catheter ablation is less clear. Data from randomized studies are urgently needed in order to further assess efficacy in this population., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
31. Eating your heart out: endogenous proteases may contribute to atrial stunning following atrial fibrillation treatment.
- Author
-
Martin AA and Townsend D
- Subjects
- Humans, Animals, Myocardial Stunning etiology, Myocardial Stunning physiopathology, Heart Atria physiopathology, Peptide Hydrolases metabolism, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation physiopathology, Atrial Fibrillation enzymology, Atrial Fibrillation etiology
- Published
- 2024
- Full Text
- View/download PDF
32. ECMO for drug-refractory electrical storm without a reversible trigger: a retrospective multicentric observational study.
- Author
-
Durães-Campos I, Costa C, Ferreira AR, Basílio C, Torrella P, Neves A, Lebreiro AM, Pestana G, Adão L, Pinheiro-Torres J, Solla-Buceta M, Riera J, Chico-Carballas JI, Gaião S, Paiva JA, and Roncon-Albuquerque R Jr
- Subjects
- Humans, Male, Retrospective Studies, Female, Middle Aged, Adult, Follow-Up Studies, Treatment Outcome, Tachycardia, Ventricular therapy, Tachycardia, Ventricular etiology, Tachycardia, Ventricular physiopathology, Spain epidemiology, Survival Rate trends, Anti-Arrhythmia Agents therapeutic use, Extracorporeal Membrane Oxygenation methods
- Abstract
Aims: Drug-refractory electrical storm (ES) is a life-threatening medical emergency. We describe the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) in drug-refractory ES without a reversible trigger, for which specific guideline recommendations are still lacking., Methods and Results: Retrospective observational study in four Iberian centres on the indications, treatment, complications, and outcome of drug-refractory ES not associated with acute coronary syndromes, decompensated heart failure, drug toxicity, electrolyte disturbances, endocrine emergencies, concomitant acute illness with fever, or poor compliance with anti-arrhythmic drugs, requiring VA-ECMO for circulatory support. Thirty-four (6%) out of 552 patients with VA-ECMO for cardiogenic shock were included [71% men; 57 (44-62) years], 65% underwent cardiopulmonary resuscitation before VA-ECMO implantation, and 26% during cannulation. Left ventricular unloading during VA-ECMO was used in 8 (24%) patients: 3 (9%) with intraaortic balloon pump, 3 (9%) with LV vent, and 2 (6%) with Impella. Thirty (88%) had structural heart disease and 8 (24%) had an implantable cardioverter-defibrillator. The drug-refractory ES was mostly due to monomorphic ventricular tachycardia (VT) and ventricular fibrillation (VF) (59%), isolated monomorphic VT (26%), polymorphic VT (9%), or VF (6%). Thirty-one (91%) required deep sedation, 44% overdrive pacing, 36% catheter ablation, and 26% acute autonomic modulation. The main complications were nosocomial infection (47%), bleeding (24%), and limb ischaemia (21%). Eighteen (53%) were weaned from VA-ECMO, and 29% had heart transplantation. Twenty-seven (79%) survived to hospital discharge (48 (33-82) days). Non-survivors were older [62 (58-67) vs. 54 (43-58); P < 0.01] and had a higher first rhythm disorder-to-ECMO interval [0 (0-2) vs. 2 (1-11) days; P = 0.02]. Seven (20%) had rehospitalization during follow-up [29 (12-48) months], with ES recurrence in 6%., Conclusions: VA-ECMO bridged drug-refractory ES without a reversible trigger with a high success rate. This required prolonged hospital stays and coordination between the ECMO centre, the electrophysiology laboratory, and the heart transplant programme., (© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
33. Gender and race-related disparities in the management of ventricular arrhythmias.
- Author
-
Yoder M, Dils A, Chakrabarti A, Driesenga S, Alaka A, Ghannam M, Bogun F, and Liang JJ
- Subjects
- Humans, Female, Male, Sex Factors, Treatment Outcome, Risk Factors, Anti-Arrhythmia Agents therapeutic use, Black or African American, Risk Assessment, Electric Countershock mortality, Electric Countershock instrumentation, Electric Countershock adverse effects, Race Factors, Primary Prevention, Healthcare Disparities ethnology, Tachycardia, Ventricular mortality, Tachycardia, Ventricular therapy, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular ethnology, Tachycardia, Ventricular physiopathology, Catheter Ablation mortality, Catheter Ablation adverse effects, Ventricular Fibrillation mortality, Ventricular Fibrillation therapy, Ventricular Fibrillation diagnosis, Ventricular Fibrillation ethnology, Defibrillators, Implantable
- Abstract
Modern studies have revealed gender and race-related disparities in the management and outcomes of cardiac arrhythmias, but few studies have focused on outcomes for ventricular arrhythmias (VAs) such as ventricular tachycardia (VT) or ventricular fibrillation (VF). The aim of this article is to review relevant studies and identify outcome differences in the management of VA among Black and female patients. We found that female patients typically present younger for VA, are more likely to have recurrent VA after catheter ablation, are less likely to be prescribed antiarrhythmic medication, and are less likely to receive primary prevention ICD placement as compared to male patients. Additionally, female patients appear to derive similar overall mortality benefit from primary prevention ICD placement as compared to male patients, but they may have an increased risk of acute post-procedural complications. We also found that Black patients presenting with VA are less likely to undergo catheter ablation, receive appropriate primary prevention ICD placement, and have significantly higher risk-adjusted 1-year mortality rates after hospital discharge as compared to White patients. Black female patients appear to have the worst outcomes out of any demographic subgroup., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
34. Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review.
- Author
-
Shaikh F, Wynne R, Castelino RL, Davidson PM, Inglis SC, and Ferguson C
- Subjects
- Humans, Middle Aged, Atrial Fibrillation drug therapy, Obesity complications, Obesity drug therapy, Anti-Arrhythmia Agents pharmacokinetics, Anti-Arrhythmia Agents therapeutic use
- Abstract
Background: Atrial fibrillation (AF) and obesity coexist in approximately 37.6 million and 650 million people globally, respectively. The anatomical and physiological changes in individuals with obesity may influence the pharmacokinetic properties of drugs., Aim: This review aimed to describe the evidence of the effect of obesity on the pharmacokinetics of antiarrhythmics in people with AF., Methods: Three databases were searched from inception to June 2023. Original studies that addressed the use of antiarrhythmics in adults with AF and concomitant obesity were included., Results: A total of 4549 de-duplicated articles were screened, and 114 articles underwent full-text review. Ten studies were included in this narrative synthesis: seven cohort studies, two pharmacokinetic studies, and a single case report. Samples ranged from 1 to 371 participants, predominately males (41%-85%), aged 59-75 years, with a body mass index (BMI) of 23-66 kg/m
2 . The two most frequently investigated antiarrhythmics were amiodarone and dofetilide. Other drugs investigated included diltiazem, flecainide, disopyramide, propafenone, dronedarone, sotalol, vernakalant, and ibutilide. Findings indicate that obesity may affect the pharmacokinetics of amiodarone and sodium channel blockers (e.g., flecainide, disopyramide, and propafenone). Factors such as drug lipophilicity may also influence the pharmacokinetics of the drug and the need for dose modification., Discussion: Antiarrhythmics are not uniformly affected by obesity. This observation is based on heterogeneous studies of participants with an average BMI and poorly controlled confounding factors such as multimorbidity, concomitant medications, varying routes of administration, and assessment of obesity. Controlled trials with stratification at the time of recruitment for obesity are necessary to determine the significance of these findings., (© 2024 The Author(s). Clinical Cardiology published by Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
35. Comparison of His-Purkinje Conduction System Pacing with Atrial-Ventricular Node Ablation and Pharmacotherapy in HFpEF Patients with Recurrent Persistent Atrial Fibrillation (HPP-AF study).
- Author
-
Zhang JF, Pan YW, Li J, Kong XG, Wang M, Xue ZM, Gao J, and Fu GS
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Bundle of His physiopathology, Cardiac Pacing, Artificial, Exercise Tolerance drug effects, Heart Rate drug effects, Multicenter Studies as Topic, Prospective Studies, Purkinje Fibers physiopathology, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Ventricular Function, Left drug effects, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation physiopathology, Atrial Fibrillation therapy, Atrial Fibrillation surgery, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Atrioventricular Node physiopathology, Atrioventricular Node surgery, Catheter Ablation adverse effects, Heart Failure physiopathology, Heart Failure therapy, Heart Failure diagnosis, Heart Failure mortality, Recurrence, Stroke Volume drug effects
- Abstract
Background: There is currently no particularly effective strategy for patients with persistent atrial fibrillation accompanying heart failure with preserved ejection fraction (HFpEF), especially with recurrent atrial fibrillation after ablation. In this study, we will evaluate a new treatment strategy for patients with persistent atrial fibrillation who had at least two attempts (≧2 times) of radio-frequency catheter ablation but experienced recurrence, and physiologic conduction was reconstructed after atrioventricular node ablation or drug therapy, to control the patient's ventricular rate to maintain a regular heart rhythm, which is called His-Purkinje conduction system pacing (HPCSP) with atrioventricular node ablation., Methods and Results: This investigator-initiated, multicenter prospective randomized controlled trial aimed to recruit 296 randomized HFpEF patients with recurrent atrial fibrillation. All the enrolled patients were randomly assigned to the pacing group or the drug treatment group. The primary endpoint is differences in cardiovascular events and clinical composite endpoints (all-cause mortality) between patients in the HPCSP and drug-treated groups. Secondary endpoints included heart failure hospitalization, exercise capacity assessed by cardiopulmonary exercise tests, quality of life, echocardiogram parameters, 6-minute walk distance, NT-ProBNP, daily patient activity levels, and heart failure management report recorded by the CIED. It is planned to compete recruitment by the end of 2023 and report in 2025., Conclusions: The study aims to determine whether His-Purkinje conduction system pacing with atrioventricular node ablation can better improve patients' symptoms and quality of life, postpone the progression of heart failure, and reduce the rate of rehospitalization and mortality of patients with heart failure., Clinical Trial Registration Number: ChiCTR1900027723, URL: http://www.chictr.org.cn/edit.aspx?pid=46128&htm=4., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
36. Acute hepatotoxicity of intravenous amiodarone in a Becker muscular dystrophy patient with decompensated heart failing and ABCB4 gene mutation: as assessed for causality using the updated RUCAM.
- Author
-
Shi H, Chen R, Li M, and Ge J
- Subjects
- Humans, Male, Adolescent, Chemical and Drug Induced Liver Injury genetics, Chemical and Drug Induced Liver Injury etiology, Atrial Fibrillation drug therapy, Amiodarone adverse effects, Amiodarone administration & dosage, Heart Failure chemically induced, ATP Binding Cassette Transporter, Subfamily B genetics, Mutation, Anti-Arrhythmia Agents adverse effects, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents administration & dosage, Muscular Dystrophy, Duchenne drug therapy, Muscular Dystrophy, Duchenne genetics, Muscular Dystrophy, Duchenne complications
- Abstract
Background: Cardiac dysfunction, including arrhythmias, may be one of the main clinical manifestations of Becker muscular dystrophy (BMD). Amiodarone is widely used to treat arrhythmia. However, multi-systemic toxicity caused by amiodarone, especially hepatotoxicity, should not be neglected. Here, we introduce a novel case of multi-systemic amiodarone toxicity involving the liver, renal and coagulation in BDM patient with ABCB4 gene mutation., Case Presentation: We present a case of a 16-year-old boy admitted with heart failure and atrial fibrillation (AF). He was diagnosed with Becker muscular dystrophy (BMD) and gene testing showed comorbid mutations in gene DMD, ABCB4 and DSC2. Amiodarone was prescribed to control the paroxysmal atrial fibrillation intravenously. However, his liver enzyme levels were sharply elevated, along with cardiac shock, renal failure and coagulation disorders. After bedside continuous renal replacement therapy, the patient's liver function and clinical status rehabilitated., Conclusions: ABCB4 gene mutation might be involved in amiodarone-induced hepatotoxicity. Studies in a cohort might help to prove this hypothesis in the future., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. Antiarrhythmic Mechanisms of Epidural Blockade After Myocardial Infarction.
- Author
-
Hoang JD, van Weperen VYH, Kang KW, Jani NR, Swid MA, Chan CA, Lokhandwala ZA, Lux RL, and Vaseghi M
- Subjects
- Animals, Swine, Lidocaine pharmacology, Anesthesia, Epidural methods, Baroreflex drug effects, Refractory Period, Electrophysiological drug effects, Anti-Arrhythmia Agents pharmacology, Anti-Arrhythmia Agents therapeutic use, Anesthetics, Local pharmacology, Ventricular Function, Right drug effects, Hemodynamics drug effects, Female, Thoracic Vertebrae, Sus scrofa, Myocardial Contraction drug effects, Male, Disease Models, Animal, Ventricular Function, Left drug effects, Myocardial Infarction physiopathology, Tachycardia, Ventricular physiopathology, Tachycardia, Ventricular etiology
- Abstract
Background: Thoracic epidural anesthesia (TEA) has been shown to reduce the burden of ventricular tachycardia in small case series of patients with refractory ventricular tachyarrhythmias and cardiomyopathy. However, its electrophysiological and autonomic effects in diseased hearts remain unclear, and its use after myocardial infarction is limited by concerns for potential right ventricular dysfunction., Methods: Myocardial infarction was created in Yorkshire pigs (N=22) by left anterior descending coronary artery occlusion. Approximately, six weeks after myocardial infarction, an epidural catheter was placed at the C7-T1 vertebral level for injection of 2% lidocaine. Right and left ventricular hemodynamics were recorded using Millar pressure-conductance catheters, and ventricular activation recovery intervals (ARIs), a surrogate of action potential durations, by a 56-electrode sock and 64-electrode basket catheter. Hemodynamics and ARIs, baroreflex sensitivity and intrinsic cardiac neural activity, and ventricular effective refractory periods and slope of restitution (S
max ) were assessed before and after TEA. Ventricular tachyarrhythmia inducibility was assessed by programmed electrical stimulation., Results: TEA reduced inducibility of ventricular tachyarrhythmias by 70%. TEA did not affect right ventricular-systolic pressure or contractility, although left ventricular-systolic pressure and contractility decreased modestly. Global and regional ventricular ARIs increased, including in scar and border zone regions post-TEA. TEA reduced ARI dispersion specifically in border zone regions. Ventricular effective refractory periods prolonged significantly at critical sites of arrhythmogenesis, and Smax was reduced. Interestingly, TEA significantly improved cardiac vagal function, as measured by both baroreflex sensitivity and intrinsic cardiac neural activity., Conclusions: TEA does not compromise right ventricular function in infarcted hearts. Its antiarrhythmic mechanisms are mediated by increases in ventricular effective refractory period and ARIs, decreases in Smax , and reductions in border zone electrophysiological heterogeneities. TEA improves parasympathetic function, which may independently underlie some of its observed antiarrhythmic mechanisms. This study provides novel insights into the antiarrhythmic mechanisms of TEA while highlighting its applicability to the clinical setting., Competing Interests: M. Vaseghi has patents related to neuromodulation at the University of California, Los Angeles, and has performed educational consulting for Biosense Webster, Medtronic, and Recor, Inc, and has shares in NeuCures and Anumana, Inc. The other authors report no conflicts.- Published
- 2024
- Full Text
- View/download PDF
38. A danish healthcare-focused economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation.
- Author
-
Hansen ML, Moss JWE, Tønnesen J, Johansen ML, Kuniss M, Ismyrloglou E, Andrade J, Wazni O, Mealing S, Sale A, Afonso D, Bromilow T, Lane E, and Chierchia GB
- Subjects
- Humans, Denmark, Treatment Outcome, Time Factors, Male, Female, Middle Aged, Decision Support Techniques, Aged, Pulmonary Veins surgery, Pulmonary Veins physiopathology, Cost Savings, Decision Trees, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Atrial Fibrillation economics, Atrial Fibrillation therapy, Atrial Fibrillation drug therapy, Atrial Fibrillation physiopathology, Cryosurgery economics, Cryosurgery adverse effects, Cost-Benefit Analysis, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents economics, Quality-Adjusted Life Years, Drug Costs, Models, Economic, Markov Chains, Quality of Life, Randomized Controlled Trials as Topic
- Abstract
Introduction: Three randomised controlled trials (RCTs) have demonstrated that first-line cryoballoon pulmonary vein isolation decreases atrial tachycardia in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drugs (AADs). The aim of this study was to develop a cost-effectiveness model (CEM) for first-line cryoablation compared with first-line AADs for the treatment of PAF. The model used a Danish healthcare perspective., Methods: Individual patient-level data from the Cryo-FIRST, STOP AF and EARLY-AF RCTs were used to parameterise the CEM. The model structure consisted of a hybrid decision tree (one-year time horizon) and a Markov model (40-year time horizon, with a three-month cycle length). Health-related quality of life was expressed in quality-adjusted life years (QALYs). Costs and benefits were discounted at 3% per year. Model outcomes were produced using probabilistic sensitivity analysis., Results: First-line cryoablation is dominant, meaning it results in lower costs (-€2,663) and more QALYs (0.18) when compared to first-line AADs. First-line cryoablation also has a 99.96% probability of being cost-effective, at a cost-effectiveness threshold of €23,200 per QALY gained. Regardless of initial treatment, patients were expected to receive ∼ 1.2 ablation procedures over a lifetime horizon., Conclusion: First-line cryoablation is both more effective and less costly (i.e. dominant), when compared with AADs for patients with symptomatic PAF in a Danish healthcare system., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
39. The potential anti-arrhythmic effect of SGLT2 inhibitors.
- Author
-
Duan HY, Barajas-Martinez H, Antzelevitch C, and Hu D
- Subjects
- Humans, Animals, Treatment Outcome, Heart Rate drug effects, Autophagy drug effects, Sodium-Glucose Transporter 2 metabolism, Action Potentials drug effects, Sodium metabolism, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 diagnosis, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects, Arrhythmias, Cardiac drug therapy, Arrhythmias, Cardiac physiopathology, Arrhythmias, Cardiac prevention & control, Arrhythmias, Cardiac metabolism
- Abstract
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorption of sodium and glucose. While many clinical trials demonstrated the tremendous potential of SGLT2i for cardiovascular diseases. 2022 AHA/ACC/HFSA guideline first emphasized that SGLT2i were the only drug class that can cover the entire management of heart failure (HF) from prevention to treatment. Subsequently, the antiarrhythmic properties of SGLT2i have also attracted attention. Although there are currently no prospective studies specifically on the anti-arrhythmic effects of SGLT2i. We provide clues from clinical and fundamental researches to identify its antiarrhythmic effects, reviewing the evidences and mechanism for the SGLT2i antiarrhythmic effects and establishing a novel paradigm involving intracellular sodium, metabolism and autophagy to investigate the potential mechanisms of SGLT2i in mitigating arrhythmias., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
40. Design and deployment of the STEEER-AF trial to evaluate and improve guideline adherence: a cluster-randomized trial by the European Society of Cardiology and European Heart Rhythm Association.
- Author
-
Sterliński M, Bunting KV, Boriani G, Boveda S, Guasch E, Mont L, Rajappan K, Sommer P, Mehta S, Sun Y, Gale CP, van Deutekom C, Van Gelder IC, and Kotecha D
- Subjects
- Humans, Female, Male, Aged, Europe, Middle Aged, Stroke prevention & control, Treatment Outcome, Research Design, Cardiology standards, Cardiology education, Anticoagulants therapeutic use, Practice Patterns, Physicians' standards, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation therapy, Atrial Fibrillation drug therapy, Atrial Fibrillation diagnosis, Guideline Adherence, Practice Guidelines as Topic
- Abstract
Aims: The aim is to describe the rationale, design, delivery, and baseline characteristics of the Stroke prevention and rhythm control Treatment: Evaluation of an Educational programme of the European society of cardiology in a cluster-Randomized trial in patients with Atrial Fibrillation (STEEER-AF) trial., Methods and Results: STEEER-AF is a pragmatic trial designed to objectively and robustly determine whether guidelines are adhered to in routine practice and evaluate a targeted educational programme for healthcare professionals. Seventy centres were randomized in six countries (France, Germany, Italy, Poland, Spain, and UK; 2022-23). The STEEER-AF centres recruited 1732 patients with a diagnosis of atrial fibrillation (AF), with a mean age of 68.9 years (SD 11.7), CHA2DS2-VASc score of 3.2 (SD 1.8), and 647 (37%) women. Eight hundred and forty-three patients (49%) were in AF at enrolment and 760 (44%) in sinus rhythm. Oral anticoagulant therapy was prescribed in 1543 patients (89%), with the majority receiving direct oral anticoagulants (1378; 89%). Previous cardioversion, antiarrhythmic drug therapy, or ablation was recorded in 836 patients (48.3%). Five hundred fifty-one patients (31.8%) were currently receiving an antiarrhythmic drug, and 446 (25.8%) were scheduled to receive a future cardioversion or ablation. The educational programme engaged 195 healthcare professionals across centres randomized to the intervention group, consisting of bespoke interactive online learning and reinforcement activities, supported by national expert trainers., Conclusion: The STEEER-AF trial was successfully deployed across six European countries to investigate guideline adherence in real-world practice and evaluate if a structured educational programme for healthcare professionals can improve patient-level care., Clinical Trial Registration: Clinicaltrials.gov, NCT04396418., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
41. Landiolol for perioperative atrial tachyarrhythmias in cardiac and thoracic surgery patients: a systematic review and meta-analysis.
- Author
-
Kowalik K, Silverman M, Oraii A, Conen D, Belley-Côté EP, Healey JS, Um KJ, Inami T, Wanner PM, Wang MK, Pandey A, Udayashankar A, Whitlock RP, Devereaux PJ, and McIntyre WF
- Subjects
- Humans, Cardiac Surgical Procedures adverse effects, Anti-Arrhythmia Agents therapeutic use, Postoperative Complications prevention & control, Thoracic Surgical Procedures adverse effects, Morpholines therapeutic use, Morpholines adverse effects, Urea analogs & derivatives, Urea therapeutic use, Urea pharmacology
- Published
- 2024
- Full Text
- View/download PDF
42. Longitudinal analysis of echocardiographic and cardiac biomarker variables in dogs with atrial fibrillation: The optimal rate control in dogs with atrial fibrillation II study.
- Author
-
Pedro B, Mavropoulou A, Oyama MA, Linney C, Neves J, Dukes-McEwan J, Fontes-Sousa AP, and Gelzer AR
- Subjects
- Animals, Dogs, Male, Female, Anti-Arrhythmia Agents therapeutic use, Electrocardiography, Ambulatory veterinary, Heart Rate, Longitudinal Studies, Peptide Fragments blood, Prospective Studies, Atrial Fibrillation veterinary, Dog Diseases blood, Dog Diseases diagnostic imaging, Echocardiography veterinary, Biomarkers blood, Natriuretic Peptide, Brain blood
- Abstract
Background: Rate control (RC; meanHR
Holter ≤ 125 bpm) increases survival in dogs with atrial fibrillation (AF). The mechanisms remain unclear., Hypothesis/objectives: Investigate echocardiographic and biomarker differences between RC and non-RC (NRC) dogs. Determine if changes post-anti-arrhythmic drugs (AAD) predict successful RC in subsequent Holter monitoring. Evaluate if early vs late RC affects survival., Animals: Fifty-two dogs with AF., Methods: Holter-derived mean heart rate, echocardiographic and biomarker variables from dogs receiving AAD were analyzed prospectively at each re-evaluation and grouped into RC or NRC. The primary endpoint was successful RC. Between group comparisons of absolute values, magnitude of change from admission to re-evaluations and end of study were performed using Mann-Whitney tests or unpaired t-tests. Logistic regression explored variables associated with inability to achieve RC at subsequent visits. Kaplan-Meier survival analysis was used to compare survival time of early vs late RC., Results: At visit 2, 11/52 dogs were RC; at visit 3, 14/52 were RC; and at visit 4, 4/52 were RC. At the end of study, 25/52 remained NRC. At visit 2, both groups had increased cardiac dimensions, but NRC dogs had larger dimensions; biomarkers did not differ. At the end of study, RC showed decreased cardiac dimensions and end-terminal pro-brain natriuretic peptide (NT-proBNP) compared with NRC. No variables were useful at predicting RC success in subsequent visits. Survival analysis found no differences between early vs late RC., Conclusions and Clinical Importance: The RC dogs had decreased cardiac dimensions and NT-proBNP, suggesting HR-mediated reverse-remodeling might benefit survival, even with delayed RC achievement. Pursuit of RC is crucial despite initial failures., (© 2024 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)- Published
- 2024
- Full Text
- View/download PDF
43. Intracardiac echocardiography guided anatomical ablation of the arcuate ridge for drug refractory inappropriate sinus tachycardia.
- Author
-
Cabrera JS, Tapias C, Adams C, Hernandez B, Bautista W, Stozitzky V, Restrepo AJ, and Saenz L
- Subjects
- Humans, Female, Retrospective Studies, Male, Middle Aged, Adult, Treatment Outcome, Action Potentials, Predictive Value of Tests, Anti-Arrhythmia Agents therapeutic use, Time Factors, Ultrasonography, Interventional, Electrocardiography, Ambulatory, Drug Resistance, Sinoatrial Node surgery, Sinoatrial Node physiopathology, Echocardiography, Tachycardia, Sinus surgery, Tachycardia, Sinus physiopathology, Catheter Ablation, Heart Rate
- Abstract
Introduction: Inappropriate sinus tachycardia (IST) is a common condition with frequently not tolerated beta-blockers or ivabradine and a high rate of complication in ablation strategy; we describe an alternative anatomical approach of sinus node (SN) modulation., Methods: This retrospective study describes a case series of 6 patients from two centers diagnosed with symptomatic IST undergoing SN ablation., Results: The mean age was 40.6 ± 13.9 years; five of the six patients were female, 100% of patients reported heart palpitations, and 66% reported dizziness, the average heart rate (HR) on a 24-h Holter was 93.2 ± 7.9 bpm. HR during the first stage of a stress test using a standard Bruce protocol was 150 ± 70 bpm, The average HR on 24-h Holter postablation was 75 ± 5.6 bpm, the sinus rate HR during stage 1 of a Bruce protocol exercise stress test was 120 ± 10 bpm., Conclusion: This is the first case series reporting the acute and long-term results of a novel anatomical approach for SN modulation to treat IST targeting the arcuate ridge (AR) under intracardiac echography (ICE) guidance. The novel anatomic ICE-guided catheter ablation approach aimed to identify the earliest activation at the AR with an extension of RF lesions toward its septal region seems effective and safe to modulate the SN in symptomatic patients with IST refractory to medical treatment., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
44. Digoxin and Risk of Ventricular Tachyarrhythmia and Death in ICD Recipients.
- Author
-
Ojo A, McNitt S, Polonsky B, Aktas MK, Rosero S, Hall B, Kutyifa V, Rao N, Rao N, and Goldenberg I
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Propensity Score, Ventricular Fibrillation mortality, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects, Cohort Studies, Risk Factors, Digoxin therapeutic use, Digoxin adverse effects, Defibrillators, Implantable adverse effects, Tachycardia, Ventricular mortality, Heart Failure mortality, Heart Failure drug therapy
- Abstract
Background: Some studies have shown digoxin use to be associated with adverse outcomes, including increased mortality. There are limited data on whether digoxin use is associated with increased risk of ventricular tachycardia/ventricular fibrillation (VT/VF) in heart failure patients with an implantable cardioverter-defibrillator (ICD)., Objectives: This study sought to assess whether digoxin use is associated with increased risk of VT/VF in patients with heart failure with reduced ejection fraction with a primary prevention ICD in landmark clinical trials., Methods: The study cohort consisted of patients with an ICD or cardiac resynchronization therapy-defibrillator who were enrolled in 4 landmark MADIT trials (Multicenter Automatic Defibrillator Implantation Trials). We employed propensity score quintile stratification for treatment with digoxin as well as additional multivariable adjustment to assess the risk of digoxin vs no-digoxin therapy for the endpoints of first and recurrent VT/VF and all-cause mortality. The proportional hazards regression models for arrhythmia-specific endpoints incorporated adjustments for the competing risk of death., Results: At baseline, 1,155 of 4,499 patients were on digoxin (26%). After propensity score quintile stratification, patients prescribed digoxin were shown to exhibit a statistically significant 48% increased risk of VT/VF (P < 0.001), 42% increased risk of the composite of VT/VF or death (P < 0.001), and a 37% increased risk of all-cause mortality (P = 0.006). Digoxin use was also associated with increased risk of appropriate ICD shocks (HR: 1.91; P < 0.001) and with increased burden of VT/VF events (HR: 1.46; P = 0.001)., Conclusions: Our findings suggests that digoxin use is associated with ventricular tachyarrhythmia and death in heart failure with reduced ejection fraction patients with an ICD., Competing Interests: Funding Support and Author Disclosures The MADIT-RISK study was supported by NIH grant HL077478. Dr Aktas has received research funding from AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Rhythm vs Rate Control Strategy for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
- Author
-
Zafeiropoulos S, Doundoulakis I, Bekiaridou A, Farmakis IT, Papadopoulos GE, Coleman KM, Giannakoulas G, Zanos S, Tsiachris D, Duru F, Saguner AM, Mountantonakis SE, and Stavrakis S
- Subjects
- Humans, Heart Rate physiology, Electric Countershock statistics & numerical data, Electric Countershock methods, Aged, Female, Male, Atrial Fibrillation therapy, Atrial Fibrillation surgery, Anti-Arrhythmia Agents therapeutic use, Randomized Controlled Trials as Topic, Catheter Ablation methods
- Abstract
Background: Rhythm control, either with antiarrhythmic drugs or catheter ablation, and rate control strategies are the cornerstones of atrial fibrillation (AF) management. Despite the increasing role of rhythm control over the past few years, it remains inconclusive which strategy is superior in improving clinical outcomes., Objectives: This study summarizes the total and time-varying evidence regarding the efficacy of rhythm- vs rate-control strategies in the management of AF., Methods: We systematically perused the MEDLINE, CENTRAL (Cochrane Central Register of Controlled Trials), and Web of Science databases for randomized controlled trials from inception to November 2023. We included studies that compared the efficacy of rhythm control (ie, antiarrhythmic drugs classes Ia, Ic, or III, AF catheter ablation, and electrical cardioversion) and rate control (ie, beta-blocker, digitalis, or calcium antagonist) strategies among patients with nonvalvular AF. The primary outcome was cardiovascular (CV) death, whereas secondary outcomes included all-cause death, stroke, hospitalization for heart failure (HF), sinus rhythm at the end of the follow-up, and rhythm control-related adverse events. A cumulative meta-analysis to assess temporal trends and a meta-regression analysis using the percentage of ablation use was performed., Results: We identified 18 studies with a total of 17,536 patients (mean age: 68.6 ± 9.7 years, 37.9% females) and a mean follow-up of 28.5 months. Of those, 31.9% had paroxysmal AF. A rhythm control strategy reduced CV death (HR: 0.78; 95% CI: 0.62-0.96), stroke (HR: 0.801; 95% CI: 0.643-0.998), and hospitalization for HF (HR: 0.80; 95% CI: 0.69-0.94) but not all-cause death (HR: 0.86; 95% CI: 0.73-1.02) compared with a rate control strategy. This benefit was driven by contemporary studies, whereas more ablation use within the rhythm control arm was associated with improved outcomes, except stroke., Conclusions: In patients with AF, a contemporary rhythm control strategy leads to reduced CV mortality, HF events, and stroke compared with a rate control strategy., Competing Interests: Funding Support and Author Disclosures Dr Saguner has received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic; and speaker/advisory board/consulting fees from Bayer Healthcare, Biotronik, Daiichi-Sankyo, Medtronic, Novartis, Pfizer, Stride Bio Inc, and Zoll; and has stock options from Gilead Sciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.
- Author
-
Kukendrarajah K, Farmaki AE, Lambiase PD, Schilling R, Finan C, Floriaan Schmidt A, and Providencia R
- Subjects
- Humans, Computational Biology methods, Genetic Association Studies methods, Genetic Predisposition to Disease, Drug Repositioning methods, Drug Discovery, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents pharmacology, Atrial Fibrillation genetics, Atrial Fibrillation drug therapy, Drug Development
- Abstract
Background: Drug development for atrial fibrillation (AF) has failed to yield new approved compounds. We sought to identify and prioritise potential druggable targets with support from human genetics, by integrating the available evidence with bioinformatics sources relevant for AF drug development., Methods: Genetic hits for AF and related traits were identified through structured search of MEDLINE. Genes derived from each paper were cross-referenced with the OpenTargets platform for drug interactions. Confirmation/validation was demonstrated through structured searches and review of evidence on MEDLINE and ClinialTrials.gov for each drug and its association with AF., Findings: 613 unique drugs were identified, with 21 already included in AF Guidelines. Cardiovascular drugs from classes not currently used for AF (e.g. ranolazine and carperitide) and anti-inflammatory drugs (e.g. dexamethasone and mehylprednisolone) had evidence of potential benefit. Further targets were considered druggable but remain open for drug development., Interpretation: Our systematic approach, combining evidence from different bioinformatics platforms, identified drug repurposing opportunities and druggable targets for AF., Funding: KK is supported by Barts Charity grant G-002089 and is mentored on the AFGen 2023-24 Fellowship funded by the AFGen NIH/NHLBI grant R01HL092577. RP is supported by the UCL BHF Research Accelerator AA/18/6/34223 and NIHR grant NIHR129463. AFS is supported by the BHF grants PG/18/5033837, PG/22/10989 and UCL BHF Accelerator AA/18/6/34223 as well as the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee EP/Z000211/1 and by the UKRI-NIHR grant MR/V033867/1 for the Multimorbidity Mechanism and Therapeutics Research Collaboration. AF is supported by UCL BHF Accelerator AA/18/6/34223. CF is supported by UCL BHF Accelerator AA/18/6/34223., Competing Interests: Declaration of interests AFS and CF have received unrestricted funding from New Amsterdam Pharma, for investigating the role of a specific drug not related to AF. CF has received funding from Pfizer investigating the role of specific drug targets not related to AF, he is not the principal investigator on this. PL has received grants from Boston Scientific and Abbott Medical as well as consulting fees from Boston Scientific. RJS has received grants, consulting fees and honoraria from Abbott medical, Biosense Webster, Boston Scientific and Medtronic., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Should We Stop Prescribing Digoxin?
- Author
-
Rattanawong P and Heist EK
- Subjects
- Humans, Atrial Fibrillation drug therapy, Anti-Arrhythmia Agents therapeutic use, Cardiotonic Agents therapeutic use, Digoxin therapeutic use
- Abstract
Competing Interests: Funding Support and Author Disclosures Dr Heist is a consultant for Biotronik, Boston Scientific, and Future Cardia. Dr Rattanawong has reported that he has no relationships relevant to the contents of this paper to disclose.
- Published
- 2024
- Full Text
- View/download PDF
48. Early Rhythm Management in Patients With Atrial Fibrillation: From Symptom Control to Adverse Outcome Reduction.
- Author
-
Linz D and Chaldoupi SM
- Subjects
- Humans, Anti-Arrhythmia Agents therapeutic use, Male, Atrial Fibrillation therapy, Atrial Fibrillation physiopathology
- Abstract
Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Published
- 2024
- Full Text
- View/download PDF
49. Body Surface Potential Mapping during Atrial Depolarization in Rats with Post-Infarction Chronic Heart Failure against the Background of Fabomotizole Therapy.
- Author
-
Smirnova SL, Roshchevskaya IM, Ivonin AG, Barchukov VV, Tsorin IB, and Kryzhanovskii SA
- Subjects
- Animals, Rats, Male, Morpholines pharmacology, Morpholines therapeutic use, Electrocardiography, Rats, Wistar, Benzimidazoles pharmacology, Benzimidazoles therapeutic use, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents pharmacology, Heart Failure drug therapy, Heart Failure physiopathology, Myocardial Infarction physiopathology, Myocardial Infarction drug therapy, Myocardial Infarction complications, Heart Atria drug effects, Heart Atria physiopathology, Body Surface Potential Mapping methods
- Abstract
Cardiac remodeling in rats with post-infarction chronic heart failure caused by anterior transmural myocardial infarction leads to an atypical location of areas of positive and negative cardioelectric potentials on the body surface before the onset of the P
II -wave on the ECG in the limb leads, which is a sign of increased heterogeneity of atrial depolarization associated with the appearance of additional excitation focus in the left atrium. A course of therapy with fabomotizole leads to a decrease in the heterogeneity of atrial depolarization at the initial stages of the formation of the cardioelectric field of the atria on the body surface before the onset of the PII -wave, thereby producing an antiarrhythmic effect., (© 2024. Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
50. Benefits of early rhythm control of atrial fibrillation.
- Author
-
Eckardt L, Wolfes J, and Frommeyer G
- Subjects
- Humans, Treatment Outcome, Time Factors, Risk Factors, Atrial Remodeling, Risk Assessment, Atrial Fibrillation physiopathology, Atrial Fibrillation diagnosis, Atrial Fibrillation therapy, Atrial Fibrillation drug therapy, Anti-Arrhythmia Agents therapeutic use, Anti-Arrhythmia Agents adverse effects, Heart Rate drug effects, Catheter Ablation adverse effects
- Abstract
In contrast to current guidelines and earlier trials, recent studies demonstrated superiority of rhythm- over rate-control and challenged the strategy of "rate versus rhythm" therapy in patients with atrial fibrillation. These newer studies have started to shift the use of rhythm-control therapy from the symptom-driven therapy of current guidelines to a risk-reducing strategy aimed at restoring and maintaining sinus rhythm. This review discusses recent data and presents an overview on the current discourse: The concept of early rhythm control seems attractive. Patients with rhythm control may undergo less atrial remodeling compared to those with rate control. In addition, in EAST-AFNET 4 an outcome-reducing effect of rhythm control was achieved by delivering therapy with relatively few complications early after the initial AF diagnosis. Successful rhythm control therapy and most likely reduced AF burden, estimated by the presence of sinus rhythm at 12 months after randomization, explained most of the reduction in cardiovascular outcomes achieved by rhythm control. However, it is too early to call for early rhythm control for all AF patients. Rhythm control may raise concerns regarding the generalizability of trial results in routine practice involving important questions on the definition of "early" and "successful", and the relevant issue of antiarrhythmic drugs versus catheter ablation. Further information is required to select patients who will benefit from an early ablative or non-ablative rhythm management., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.